Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa
Sanofi-aventis Healthcare Pty Ltd
Hidradenitis suppurativa
1 trial -
A sterile preservative-free solution with identical composition as the drug product, but without the protein.
Kiniksa Pharmaceuticals International, plc
Sjรถgrenโs Disease
1 trial -
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouth
Sanofi-aventis Healthcare Pty Ltd
Healthy volunteers
1 trial -
A-101 Topical Solution 40%
Aclaris Therapeutics
Dermatosis Papulosa Nigra
1 trial -
A-623
Santhera Pharmaceuticals (Deutschland) GmbH
Systemic Lupus Erythematosus
1 trial -
A.1 Lucinactant
WINDTREE THERAPEUTICS INC /DE/
Acute Respiratory Distress Syndrome
1 trial -
AAV2-hAADC
PTC THERAPEUTICS, INC.
Aromatic Amino Acid Decarboxylase Deficiency
1 trial -
AB8939, Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets
AB Science
Acute Myeloid Leukemia
1 trial -
ABBV-066, Lutikizumab
AbbVie Deutschland GmbH & Co. KG
Psoriatic Arthritis
1 trial -
ABBV-066, Lutikizumab, ABBV-382, ABBV-066 / Risankizumab, ABBV-8736
AbbVie Deutschland GmbH & Co. KG
Moderate to Severe Crohnโs Disease
1 trial -
ABIRATERONE, DAROLUTAMIDE, DZR123, -, -, ABIRATERONE, DZR123, DAROLUTAMIDE
Novartis Pharmaceuticals
Metastatic hormone-sensitive prostate cancer
1 trial -
ABTL0812, IRINOTECAN, TEMOZOLOMIDE
The George Institute
Relapsed/refractory neuroblastoma and other solid tumours
1 trial -
AC102-Suspension 12 mg/ml, placebo gel, Placebo matching Prednisolone, Prednisolon 10 mg GALENยฎ
Lacuna Pharma Pty Ltd
Idiopathic Sudden Sensorineural Hearing Loss
1 trial -
ACETYLCYSTEINE , DEXAMETHASONE , DIPHENHYDRAMINE , GLUCOSE
Inhibrx Biosciences
Unresectable or metastatic conventional chondrosarcoma
1 trial -
ACP-211
Acadia Pharmaceuticals B.V.
Major Depressive Disorder (MDD)
1 trial -
ACR-368
Acrivon Therapeutics
Endometrial Adenocarcinoma
1 trial -
ADALIMUMAB, USTEKINUMAB , ADALIMUMAB , USTEKINUMAB, Olumiant 4 mg film-coated tablets
Pari Pharma GmbH
Folliculitis decalvans
1 trial -
ADCETRIS 50 mg powder for concentrate for solution for infusion
Takeda
Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a โฅ50 Lansky Play-Performance or Karnofsky Performance Status.
1 trial -
ADCETRIS 50 mg powder for concentrate for solution for infusion, DACARBAZINE , DOXORUBICIN , DEXAMETHASONE , VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE
Ningbo Cancer Hospital
Advanced stage Hodgkin Lymphoma
1 trial -
ADENOVIRUS/PSA VACCINE
United Therapeutics Europe Ltd
Hormone Refractory Prostate Cancer
1 trial -
ADSC01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Connective Tissue Diseases
1 trial -
ADSTILADRIN
Ferring Pharmaceuticals
Low-grade upper track urothelial carcinoma (LG-UTUC)
1 trial -
ADX-038, Sodio cloruro Galenica Senese 0,9% solvente per uso parenterale
Lacuna Pharma Pty Ltd
Geographic atrophy secondary to age-related macular degeneration
1 trial -
ADX-102 Ophthalmic Drops (0.5%)
Aldeyra Therapeutics
Conjunctivitis, Allergic
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources